Hunan Jiudian Pharmaceutical: Transdermal Patch Leader Navigating Post-VBP Transformation and Innovation-Driven Growth
Hunan Jiudian Pharmaceutical (300705.SZ) stands as a leading player in China's transdermal drug delivery market, with its flagship product loxoprofen sodium gel patch having historically commanded 100% market share. However, the inclusion of this product in China's 11th round of centralized volume-based procurement (VBP) in 2025, with a price cut of 74.25%, has fundamentally altered the company's growth trajectory. FY2025 revenue grew modestly by 6.15% to RMB 3.111 billion (USD 430.28 million), while net income declined by 7.72% to RMB 473 million (USD 65.42 million), marking the first profit decline in five years. The company is executing a dual-track strategy: defending its core patch franchise through new product launches (loxoprofen patch first generic, flurbiprofen gel patch) and pursuing an aggressive transformation toward innovative drug R&D, focusing on pain management and oncology. With an integrated industrial chain spanning formulations, APIs, and excipients, Jiudian maintains structural cost advantages. Near-term earnings pressure from VBP is expected to persist through 2026, but the long-term outlook hinges on pipeline execution and brand building.
1. Company Overview
Hunan Jiudian Pharmaceutical Co., Ltd. (stock code: 300705.SZ) was founded in 2001 and listed on the Shenzhen Stock Exchange in October 2017. Headquartered in Changsha, Hunan Province, the company has evolved from a traditional chemical pharmaceutical manufacturer into a diversified pharmaceutical enterprise with operations spanning chemical drug formulations, active pharmaceutical ingredients (APIs), pharmaceutical excipients, traditional Chinese medicines, health products, and pharmaceutical CXO services.
The company operates three major production and R&D bases: the Liuyang formulation park, the Wangcheng API and excipient park, and the Lugu R&D and office park, forming an integrated 'three-park' development layout. As of the end of 2025, Jiudian had over 475 R&D personnel, more than 200 marketing authorizations and production approvals, 153 authorized patents, and 60+ modern production lines. Its products are distributed across more than 60 countries and regions, with API and excipient exports reaching Europe, America, Japan, and other regulated markets.
FY2025 was a pivotal year for Jiudian, marked by the national VBP inclusion of its flagship product. The company reported revenue of RMB 3.111 billion (USD 430.28 million at 7.23 CNY/USD), representing 6.15% year-over-year growth. However, net income attributable to shareholders declined 7.72% to RMB 473 million (USD 65.42 million), the first annual profit decline in five years. The divergence between revenue growth and profit decline reflects the structural shift underway: the core gel patch product experienced severe price erosion, while new product launches and the API/excipient business provided partial offset.
2. Business Model & Core Operations
Jiudian's business model is anchored on an integrated 'formulation + API + excipient' value chain, which provides both cost advantages and quality control capabilities. The company's revenue structure in FY2025 was as follows: pharmaceutical formulations contributed RMB 2.532 billion (81.40% of revenue) with a gross margin of 82.26%; APIs contributed RMB 259 million (8.34%) at 33.21% gross margin; and pharmaceutical excipients contributed RMB 194 million (6.23%) at 32.31% gross margin.
The formulation segment is further divided into external-use preparations (patches) and oral preparations. The transdermal patch portfolio includes both chemical drug patches (loxoprofen sodium gel patch, ketoprofen gel patch, flurbiprofen gel patch) and traditional Chinese medicine patches (Daiwenjiu plaster, Qiangyao Zhuanggu plaster). The company holds 14 external-use formulation registration certificates and has more than 15 pipeline products under development, with 9 already submitted for production approval.
The oral formulation business holds over 180 product approvals, with more than 40 varieties having passed consistency evaluation and 10 selected in national VBP programs. The API and excipient business has registered over 200 varieties, with more than 130 converted to 'A' status, and serves as a stable cash-generating unit with export presence in 60+ countries.
Sales are conducted primarily through distributor partnerships under two models: 'agency recruitment' (招商代理) and 'cooperative distribution' (合作经销). Domestic customers are mainly large pharmaceutical commercial distribution companies, and the company has established a nationwide marketing network covering all provinces, autonomous regions, and municipalities.
3. Market Position & Competition
Jiudian's historical market position was built almost entirely on loxoprofen sodium gel patch, which upon its 2017 launch as China's first generic and exclusive dosage form, captured 100% of the market following the originator's exit. This single product drove revenue growth from RMB 535 million in 2017 to RMB 3.111 billion in 2025, with the product accounting for approximately 45% of total revenue at its peak.
However, the competitive landscape has undergone dramatic transformation. The product's inclusion in the 11th national VBP round in 2025 triggered a 74.25% price reduction. As of July 2026, 17 pharmaceutical companies have obtained consistency evaluation approval for loxoprofen sodium gel patch, transforming the market from a monopoly into a fiercely competitive arena.
In response, Jiudian is executing a multi-pronged defensive strategy. The company secured first-generic approval for loxoprofen sodium patch (a different dosage form) in July 2026, alongside Guangdong Renxiang Pharmaceutical. It also launched flurbiprofen gel patch in May 2026, directly entering the territory of Beijing Tide Pharmaceutical, which had previously dominated that product category. Beijing Tide had already obtained approval for loxoprofen sodium gel patch in January 2025, creating a situation where the two industry leaders are now attacking each other's core franchises.
The company's brand strategy has been elevated with the launch of the 'Jiudian Pain Relief Expert' (九典镇痛先生) brand identity in collaboration with Huayu Hua, positioning Jiudian as a 'pain relief patch specialist' and driving a shift from product-driven to brand-and-product dual-driven growth.
4. AI & Semiconductor Alignment
This section is not directly applicable. Hunan Jiudian Pharmaceutical operates in the pharmaceutical and healthcare sector, with core competencies in transdermal drug delivery, chemical drug formulations, and pharmaceutical excipients. The company does not have material exposure to artificial intelligence or semiconductor industries. Its R&D activities focus on pharmaceutical innovation, including peptide drugs, small molecule drugs, and PDC (peptide-drug conjugate) oncology therapeutics.
While the company employs advanced manufacturing technologies such as automated production lines and GMP-compliant intelligent manufacturing systems, these are operational efficiency tools rather than AI or semiconductor business lines. Investors evaluating Jiudian should focus on pharmaceutical sector dynamics, including VBP policy impacts, pipeline progression, and competitive dynamics in the transdermal patch market.
5. Customer & Regional Analysis
Jiudian's customer base is predominantly domestic, with international business representing a relatively small portion of total revenue. The company's domestic customers are primarily large pharmaceutical commercial distribution companies that handle the logistics and distribution of its products to hospitals and retail pharmacies nationwide.
The sales network is organized through multiple business divisions: Clinical Business Unit, OTC Business Unit, API/Excipient Business Unit, International Expansion Department, E-commerce Department, and Jiudian Pharmacy. This structure enables independent performance assessment and specialized market coverage.
Regionally, East China remains the largest market for Jiudian, consistent with the region's higher population density, healthcare expenditure levels, and concentration of medical institutions. The company has been actively expanding into the out-of-hospital (院外) market, including retail pharmacies and e-commerce platforms. Tmall and JD.com flagship stores have been established and underwent brand refreshment in 2026, supporting the 'buy Jiudian for patches' brand campaign.
For the API and excipient business, international markets are more significant. Products are exported to over 60 countries and regions, including Europe, America, Japan, and South Korea. Key international customers include GSK, Sanofi, and Takeda Pharmaceutical. The API segment has developed four export products with annual sales exceeding RMB 10 million each, and multiple products have obtained international registrations or certifications including EU GMP and US FDA approvals.
6. Economic Moat Analysis
The company's economic moat is derived from several sources, though its durability has been tested by VBP policy changes.
First, the integrated industrial chain spanning formulations, APIs, and excipients creates a structural cost advantage. By self-producing key APIs and excipients, Jiudian can control quality and costs from the source, enabling competitive bidding pricing while maintaining reasonable margins even under VBP pressure. This integration also facilitates reverse customization of excipients for proprietary formulation needs and accelerates R&D iteration between excipients and formulations.
Second, the company benefits from first-mover advantages in transdermal drug delivery. With nearly a decade of experience in gel patch development and manufacturing since the 2017 launch of loxoprofen sodium gel patch, Jiudian has accumulated deep expertise in hydrogel matrix cross-linking and transdermal penetration technologies. This technical know-how creates barriers to entry that are not easily replicated.
Third, the company has established a comprehensive nationwide sales network and long-standing relationships with major pharmaceutical distributors, providing distribution reach that new entrants would need years to replicate.
However, the moat has shown significant erosion. The 74.25% VBP price cut and entry of 17 competitors have demonstrated that regulatory policy can rapidly erode market exclusivity advantages in China's pharmaceutical sector. The company's future moat will depend more on portfolio breadth, brand equity, and innovation capabilities than on any single product's exclusivity.
7. Unique Competitive Advantages
Jiudian possesses several distinctive competitive advantages that differentiate it from peers in China's pharmaceutical landscape.
The most prominent advantage is its position as China's leading transdermal patch specialist. The company has built a comprehensive portfolio of chemical and traditional Chinese medicine patches that address different patient needs and preferences. Chemical patches provide cooling sensations suitable for chronic pain and sports injuries, while TCM patches offer warming effects for cold-dampness syndromes and patient populations preferring traditional therapies. This dual-category strategy allows Jiudian to capture a broader spectrum of the pain management market.
The second major advantage is the company's strategic pivot toward innovative drug development. Jiudian has transitioned from a generic-focused model to a 'generic + innovative' hybrid, with clear focus areas: pain management (peptide drugs and small molecules) and oncology (PDC drugs). The company has established dual R&D centers in central China and the Yangtze River Delta region, leveraging the former's clinical resources and cost advantages alongside the latter's talent pool and innovation ecosystem.
The company's pipeline includes multiple innovative candidates: JIJ02 gel for acne treatment (licensed from Chengdu Peide for RMB 90 million) is entering Phase II clinical trials; Jiaqi Zhitong gel patch (a Class 1.1 TCM innovative drug) has been submitted for production approval; and JIZM01 and JIZM02 have received clinical trial approvals. Another TCM innovative drug is in preclinical stage.
Third, Jiudian's API and excipient platform provides both revenue diversification and strategic supply chain security. The company is one of China's largest API and excipient manufacturers by variety, with 200+ registered products. This business generates stable cash flows and provides a hedge against formulation segment volatility.
8. R&D and Technological Capability
Jiudian maintains a substantial R&D commitment, with total R&D investment of RMB 237 million in 2025, representing 7.63% of revenue. The company has 475 R&D personnel and operates through multiple research platforms including a National Enterprise Technology Center, a Postdoctoral Research Workstation, and several provincial-level innovation platforms.
The R&D organization has been restructured to support the innovative drug transformation. A dedicated Innovative Drug Research Institute has been established, and the company recruited a prominent overseas-educated PhD to lead Jiudan Shannuo Innovative Drug Company, focusing on innovative drug R&D and technology collaboration.
Key technology platforms include:
- Transdermal drug delivery systems: hydrogel matrix cross-linking, transdermal penetration enhancement, and controlled-release technologies
- Peptide drug development: for pain management applications
- PDC (peptide-drug conjugate) technology: for oncology applications
- Small molecule drug discovery: focused on pain and inflammation targets
- TCM innovative drug development: leveraging traditional formulations with modern pharmaceutical technologies
The company adopts a dual approach of independent R&D and project acquisition to accelerate pipeline buildout. The RMB 90 million acquisition of JIJ02 gel from Chengdu Peide exemplifies this strategy. JIJ02 is a 12-amino-acid peptide with broad-spectrum antibacterial properties, physical bactericidal mechanism, low drug resistance potential, and low production cost—characteristics that suggest significant competitive advantages in the acne treatment market.
However, R&D investment declined 9.07% year-over-year in 2025, and the company terminated its previous 'new drug R&D' project, redirecting funds toward a RMB 184.6 million antibacterial peptide drug R&D program. This restructuring reflects the challenges of balancing near-term profitability with long-term innovation investments.
9. Industry Analysis
China's external patch market represents a substantial and growing opportunity. According to data cited by the company, the total market size reached approximately RMB 28.1 billion in 2025, with TCM patches accounting for 63.5% and chemical drug patches for 36.5%. The overall external patch market grew at a compound annual rate of 10.27% from 2023 to 2025, while the chemical patch segment grew even faster at 17.08%.
The chemical patch market within China's top-tier hospitals exceeded RMB 7 billion in 2024, growing approximately 10% year-over-year, and surpassed RMB 4 billion in the first half of 2025 alone, growing approximately 15%.
Several structural drivers support continued growth:
- Aging population: China's 60+ population has a 50% incidence rate of knee osteoarthritis, creating massive demand for pain management solutions.
- Rising pain awareness: Increasing recognition of pain management as a medical priority.
- Sports and fitness trends: Growing participation in sports and fitness activities is driving demand for sports injury recovery products.
- Younger demographic adoption: Pain issues are increasingly affecting younger populations, expanding the addressable market.
- Formulation advantages: Gel patches offer superior patient compliance, controlled release, and reduced systemic side effects compared to oral NSAIDs.
However, the industry also faces significant headwinds. VBP policies have fundamentally altered the economics of generic drugs, compressing margins across the sector. The loxoprofen sodium gel patch market, once a monopoly, now has 17 approved competitors, and further price erosion is likely as additional products enter VBP programs. The company's ability to maintain profitability will depend on portfolio diversification, cost leadership through vertical integration, and successful migration to higher-value innovative products.
10. Investment Conclusion & Enterprise Quality
Hunan Jiudian Pharmaceutical is a company in transition, navigating the challenging aftermath of VBP inclusion for its flagship product while attempting to build a more diversified and innovation-driven business model.
Near-term outlook (2026-2027): Earnings pressure will persist as the full-year impact of the 74.25% loxoprofen gel patch price cut flows through. Sell-side analysts have significantly revised down earnings forecasts, with 2026 net income projections ranging from RMB 300-319 million, representing a decline of approximately 32-37% from 2025 levels. The 2026 H1 results already showed revenue down 14.89% and net income down 45.21% year-over-year.
Medium-term catalysts: New product launches including loxoprofen sodium patch (first generic), flurbiprofen gel patch, and the innovative TCM drug Jiaqi Zhitong gel patch could drive revenue recovery. The API and excipient business continues to grow steadily (2026 H1 revenue up 22%, net profit up 93% for subsidiary Jiudian Hongyang). Brand building initiatives and out-of-hospital channel expansion may provide incremental growth.
Long-term thesis: The transformation to innovative drug development represents the critical long-term value driver. The company's focus on pain management and oncology, leveraging peptide and PDC technologies, positions it in attractive therapeutic areas. However, the innovative pipeline is still early-stage, with most candidates in preclinical or Phase I/II stages, and significant execution risk remains. The company's ability to successfully commercialize innovative products, potentially through out-licensing or partnership deals, will determine whether the current earnings trough represents a buying opportunity or a structural decline.
Enterprise quality assessment: Jiudian demonstrates several positive quality characteristics: consistent dividend payments (RMB 4.00 per 10 shares for 2025), a strong balance sheet with net assets of RMB 2.659 billion, and operating cash flow of RMB 647 million that significantly exceeds net income, indicating high earnings quality. The integrated industrial chain provides a durable cost advantage. However, the company's historical over-reliance on a single product and the demonstrated vulnerability to policy changes are governance concerns that investors should monitor. The success of the strategic pivot will be the key determinant of long-term enterprise value.
Valuation context: Based on post-VBP earnings forecasts, the stock trades at approximately 17x 2026E PE, which appears reasonable for a company with stabilizing core operations and optionality from an early-stage innovative pipeline. However, the risk of further VBP rounds affecting other products and the uncertainty of innovative drug development warrant a cautious approach. The investment case ultimately rests on whether investors believe the company can successfully transition from a generic-focused manufacturer to an innovation-driven pharmaceutical enterprise.